Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Aytu BioPharma Reports $16.1 Million Q4 Revenue as EXXUA Reaches $3.9 Million

None

Aytu BioPharma (AYTU) reported fiscal 2026 fourth-quarter net revenue of $16.1 million, up 6.4% from $15.1 million a year earlier. GAAP net loss was $15,000, or $0.00 per basic and diluted share, compared with a $19.8 million loss in the prior-year quarter.

For fiscal 2026, revenue totaled $57.6 million, down 13.3% from $66.4 million in fiscal 2025, while the company reported a GAAP net loss of $14.3 million, or $1.16 per share. Cash and cash equivalents were $26.3 million at June 30, 2026.

  • EXXUA generated $3.9 million in fourth-quarter revenue and $6.6 million for fiscal 2026.
  • Fourth-quarter EXXUA prescriptions totaled 3,323, up about 138% from 1,398 in the third quarter.
  • ADHD Portfolio revenue was $10.4 million in the quarter, versus $13.1 million a year earlier.
  • Pediatric Portfolio revenue was $1.8 million, compared with $2.0 million in the prior-year quarter.
  • Fourth-quarter adjusted EBITDA was $0.5 million; full-year adjusted EBITDA was a loss of $3.7 million.

$AYTU Hedge Fund Activity

We have seen 15 institutional investors add shares of $AYTU stock to their portfolio, and 11 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles